Arbutus Biopharma (ABUS) Shares Up 5.4%

Arbutus Biopharma Corp (NASDAQ:ABUS) shares shot up 5.4% during mid-day trading on Friday . The company traded as high as $2.77 and last traded at $2.72. 626,133 shares were traded during mid-day trading, an increase of 154% from the average session volume of 246,072 shares. The stock had previously closed at $2.58.

ABUS has been the topic of a number of recent research reports. Echelon Wealth Partners reaffirmed a “hold” rating on shares of Arbutus Biopharma in a research report on Monday, March 11th. Zacks Investment Research raised Arbutus Biopharma from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Tuesday, March 12th. Chardan Capital reaffirmed a “buy” rating and set a $6.50 price target on shares of Arbutus Biopharma in a research report on Sunday, March 10th. Finally, BidaskClub raised Arbutus Biopharma from a “hold” rating to a “buy” rating in a research report on Tuesday, March 5th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Arbutus Biopharma presently has an average rating of “Buy” and a consensus price target of $6.25.

The stock has a market cap of $154.33 million, a P/E ratio of -2.67 and a beta of 1.77.

Arbutus Biopharma (NASDAQ:ABUS) last issued its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02. Arbutus Biopharma had a negative return on equity of 74.52% and a negative net margin of 986.23%. The firm had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $0.77 million. As a group, equities analysts forecast that Arbutus Biopharma Corp will post -1.28 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Legal & General Group Plc lifted its position in shares of Arbutus Biopharma by 15.8% during the 4th quarter. Legal & General Group Plc now owns 28,407 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 3,867 shares during the last quarter. BNP Paribas Arbitrage SA purchased a new stake in Arbutus Biopharma during the 1st quarter worth about $26,000. Teachers Advisors LLC lifted its holdings in Arbutus Biopharma by 12.5% during the 3rd quarter. Teachers Advisors LLC now owns 75,945 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 8,428 shares in the last quarter. Bailard Inc. lifted its holdings in Arbutus Biopharma by 5.6% during the 1st quarter. Bailard Inc. now owns 228,000 shares of the biopharmaceutical company’s stock worth $816,000 after purchasing an additional 12,000 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in Arbutus Biopharma by 45.9% during the 4th quarter. Rhumbline Advisers now owns 49,032 shares of the biopharmaceutical company’s stock worth $188,000 after purchasing an additional 15,416 shares in the last quarter. 43.08% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Arbutus Biopharma (ABUS) Shares Up 5.4%” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/04/26/arbutus-biopharma-abus-shares-up-5-4.html.

Arbutus Biopharma Company Profile (NASDAQ:ABUS)

Arbutus Biopharma Corp. is a biopharmaceutical company, engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.

Read More: What is a capital gain?

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.